CMO Dr. Andrew Hertler on the Recent FDA ODAC Meeting
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncol...
The acquisition of IPG expected to accelerate Evolent Health's position as a leading provider of value-based specialty care solutions.
New Century Health and Humana's national partnership improves patient experience and eases administrative burdens on provider practices.
How do social determinants of health impact outcomes in cancer care? New Century Health Associate CMO Dr. Monica Soni and Radiation Oncologist Dr. Onyinye Balogun discuss.
New Century Health and our Vital Decisions solution seek to ensure more cancer patients receive end-of-life care that aligns with their wishes.
NCH’s high-value clinical oncology pathways, patient triage programs and provider engagement strategies help community practice to succeed in value-based payment program.
The predicted wave of late-stage cancers is taking longer to materialize than we expected.
Which components of the recently announced Cancer Moonshot should get high priority for the initiative to succeed? Our chief medical officer, Dr. Andrew Hertler, outlines three key questions to track.
New Century Health Associate Chief Medical Officer Monica Soni explores health inequities in cancer cares and shares strategies for how to address them.
Dr. Andrew Hertler explains three key criteria for evaluating fast-tracked drugs.
Confronting the heart-wrenching, avoidable circumstances that happen in hospitals and homes every day.
Red flags cause clinical reviewers to question a radiation oncologist’s diagnosis.
Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.
Home-based chemotherapy infusions may offer convenience but also raise a host of questions.
Discussing drug costs should be a core tenet of shared decision-making.
Sotunde is president and CEO of Blue Cross and Blue Shield of North Carolina.
Partnership will empower members with serious illness to articulate and advocate for the care they want.
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
Our CMO speaks with Managed Care Executive about the promise and perils of genomic testing.
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.